Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2022

Caitlin E. Cox

December 01, 2022

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2022

Shelley Wood

February 28, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

Caitlin E. Cox

October 11, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Daily News

FDA Approves Dabigatran for VTE in Children

Shelley Wood

June 22, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Industry News

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

April 26, 2018

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

CME

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

What’s Going to Be Hot at ESC 2022?

TCTMD’s Top 10 Most Popular Stories for February 2022

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

FDA Approves Dabigatran for VTE in Children

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Latest Data in Renal Denervation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content